Variant annotation and clinical interpretation (ACMG/AMP guidelines)
The systematic process of assigning pathogenicity and clinical significance to genetic variants using the standardized framework of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
This skill is the critical bridge between raw genomic sequencing data and actionable clinical diagnosis, directly enabling precision medicine initiatives. Mastery ensures diagnostic accuracy, reduces reporting errors, and is fundamental for obtaining CLIA/CAP accreditation for clinical laboratories.
1Careers
1Categories
9.2 Avg Demand
15%
Avg AI Risk
How to Learn Variant annotation and clinical interpretation (ACMG/AMP guidelines)
1. Foundational Nomenclature: Master HGVS nomenclature for variant description (e.g., c.123A>T, p.Arg41Trp) and understand the central dogma (DNA -> RNA -> protein). 2. Core ACMG/AMP Framework: Memorize the 28 evidence criteria codes (e.g., PS1, PM2, BA1) and understand their hierarchical strength (Pathogenic, Likely Pathogenic, VUS, Likely Benign, Benign). 3. Primary Databases: Learn to navigate ClinVar, gnomAD, and HGMD (if licensed) to check population frequency and prior interpretations.
1. Evidence Integration & Scoring: Practice applying the ACMG/AMP combining rules (e.g., 1 Very Strong + 1 Strong = Pathogenic) to real variant case studies from ClinVar. Avoid the common mistake of over-relying on *in silico* predictions (PP3/BP4) without supporting functional data. 2. Literature Curation: Develop a systematic workflow for searching and evaluating PubMed literature for functional studies and segregation data to satisfy PS3/PM3 criteria. 3. Gene-Disease Validity: Understand how to assess gene-disease relationships using the ClinGen framework to correctly apply PS2/PM1 criteria.
1. Custom Rule Modification: Lead the development of laboratory-specific Standard Operating Procedures (SOPs) that adapt ACMG/AMP guidelines for specific gene panels (e.g., cardiac, epilepsy) using ClinGen's expert panel frameworks. 2. Ambiguous Variant Resolution: Master the interpretation of complex variants like deep intronic, synonymous, and mosaic variants by integrating splicing prediction tools (e.g., SpliceAI) and RNA assays. 3. Strategic Reporting: Architect clinical reports that effectively communicate nuanced VUS findings and residual risk to clinicians, integrating phenotype (HPO terms) for automated tools like Exomiser.
Practice Projects
Beginner
Project
ACMG/AMP Classification of a Single Nucleotide Variant (SNV)
Scenario
You receive a VCF file from a targeted gene panel for a patient with hereditary breast cancer. One variant is a missense change in BRCA1: NM_007294.4:c.5335G>A (p.Asp1779Asn). It is absent in gnomAD and has conflicting interpretations in ClinVar.
How to Execute
1. Verify the variant annotation in Alamut Visual or IGV. 2. Check gnomAD for population frequency (<0.0001 for PM2). 3. Query ClinVar and InterVar for prior classifications and evidence codes. 4. Use the ACMG/AMP flowchart: apply PM2 (absent in controls), PP3 (multiple *in silico* tools predict deleterious), and evaluate for PM1 (located in functional domain?) and PS3 (any functional studies?). Assign a final class (e.g., Likely Pathogenic).
Intermediate
Case Study/Exercise
Resolving a Variant of Uncertain Significance (VUS) with Functional Data
Scenario
A cardiomyopathy panel returns a VUS in TTN (c.59923A>G). *In silico* tools are neutral. No ClinVar entry. You must decide whether to report it as VUS or recommend further investigation.
How to Execute
1. Analyze the variant's position in the protein context (e.g., is it in a critical A-band domain?). 2. Use SpliceAI to assess potential splicing impact (criteria PP3/BP4). 3. Search literature for functional studies on nearby TTN variants. 4. Consult the ClinGen Cardiomyopathy Expert Panel's specifications for TTN truncating variants (PS1 rule application). 5. Document the rationale for final VUS classification in the report appendix, citing specific rule limitations.
Advanced
Project
Developing a Gene-Specific Interpretation Protocol
Scenario
Your lab is launching a hereditary cancer panel including the gene CHEK2. Standard ACMG rules are too broad, leading to inconsistent VUS interpretations. You need a customized, evidence-based protocol.
How to Execute
1. Review all ClinGen-approved expert panel specifications for relevant genes (e.g., APC, TP53). 2. Systematically curate all published CHEK2 functional and segregation studies. 3. Define clear, data-driven rules to upgrade/downgrade evidence (e.g., 'Frameshifts in exon 10-15 are automatically Pathogenic per ClinGen; missense variants in the kinase domain require PS3 evidence from ≥2 independent assays'). 4. Draft an SOP with flowcharts and example cases. 5. Validate the protocol on 50 historical VUS cases and calculate inter-observer concordance.
Alamut Visual is the clinical-grade interface for splicing and missense prediction. InterVar automates ACMG/AMP rule application. Franklin and VarSome provide integrated databases and classification engines for rapid preliminary analysis. Use Alamut for final manual review.
ClinVar is the definitive public archive for clinical interpretations. gnomAD provides essential population frequency data. HGMD is a curated literature database (requires subscription). ClinGen resources provide validated gene-disease validity and variant curation frameworks.
The ACMG/AMP guidelines are the core decision-making framework. ClinGen Expert Panels provide gene-specific rule modifications and are the gold standard for clinical labs. Strict adherence to HGVS nomenclature is non-negotiable for unambiguous communication.
Interview Questions
Answer Strategy
The interviewer is testing systematic methodology and understanding of evidence hierarchy. Structure your answer using the ACMG/AMP framework explicitly. Sample Answer: 'I start by applying PM2 if it's absent in gnomAD. I then integrate multiple *in silico* tools (REVEL, CADD, SpliceAI) for PP3/BP4, but with the caveat that these are supporting, not standalone, evidence. I then perform exhaustive literature review for any indirect functional data (PS3) or segregation (PM3). If all criteria are insufficient for a definitive call, I classify as VUS and document the specific missing evidence types-like lack of functional assays or co-segregation data-to guide future testing.'
Answer Strategy
This tests communication skills, adherence to professional standards, and grace under pressure. The core competency is maintaining scientific integrity while managing stakeholder relationships. Sample Answer: 'I would first acknowledge the urgency and validate their concern. Then, I would schedule a call to review the variant evidence line-by-line using the ACMG framework, explaining why the current data doesn't meet Pathogenic criteria. I would propose a concrete action plan: e.g., offer to perform familial segregation analysis if DNA from parents is available, or coordinate with a research lab for a functional assay. This maintains the lab's credibility while actively partnering on a solution.'
Careers That Require Variant annotation and clinical interpretation (ACMG/AMP guidelines)